英文药名：Azithromycin Powder for Oral Suspension(azithromycin) 中文药名：阿奇霉素粉口服混悬液 生产厂家：山德士公司 给药介绍 适应症 1．化脓性链球菌引起的急性咽炎、急性扁桃体炎。 2．敏感细菌引起的鼻窦炎、中耳炎、急性支气管炎、慢性支气管炎急性发作。 3．肺炎链球菌、流感嗜血杆菌以及肺炎支原体所致的肺炎。 4．沙眼衣原体及非多种耐药淋病奈瑟菌所致的尿道炎和宫颈炎。 5．敏感细菌引起的皮肤软组织感染。 用法用量 口服，在饭前1小时或饭后2小时服用。 成人用量： (1)沙眼衣原体或敏感淋病奈瑟菌所致性传播疾病，仅需单次口服本品1.0g； (2)对其他感染的治疗：第1日，0.5g顿服，第2～5日，一日0.25g顿服；或一日0.5g顿服，连服3日。 小儿用量： (1)治疗中耳炎、肺炎，第1日，按体重10mg/kg顿服(一日最大量不超过0.5g)，第2～5日，每日按体重5mg/kg顿服(一日最大量不超过0.25g)或按如下方法给药： (2)治疗小儿咽炎、扁桃体炎，一日按体重12mg/kg顿服(一日最大量不超过0.5g)，连用5日。 不良反应 服药后可出现腹痛、腹泻(稀便)、上腹部不适(疼痛或痉挛)、恶心、呕吐等胃肠道反应，其发生率明显较红霉素低。偶可出现轻至中度腹胀、头昏、头痛及发热、皮疹、关节痛等过敏反应，过敏性休克和血管神经性水肿、胆汁淤积性黄疸极为少见。少数患者可出现一过性中性粒细胞减少、血清氨基转移酶升高。 禁忌 对阿奇霉素、红霉素或其他任何一种大环内酯类药物过敏者禁用。 注意事项 1．进食可影响阿奇霉素的吸收，故需在饭前1小时或饭后2小时口服。 2．轻度肾功能不全患者(肌酐清除率]40ml/分钟)不需作剂量调整，但阿奇霉素对较严重肾功能不全患者中的使用尚无资料，给这些患者使用阿奇霉素时应慎重。 3．由于肝胆系统是阿奇霉素排泄的主要途径，肝功能不全者慎用，严重肝病患者不应使用。用药期间定期随访肝功能。 4．用药期间如果发生过敏反应(如血管神经性水肿、皮肤反应、Stevous-Jonson综合征及毒性表皮坏死等)，应立即停药，并采取适当措施。 5．治疗期间，若患者出现腹泻症状，应考虑假膜性肠炎发生。如果诊断确立，应采取相应治疗措施，包括维持水、电解质平衡、补充蛋白质等。 生产商： 英国山德士公司 Azithromycin 200mg/5ml Powder for Oral Suspension 1. Name of the medicinal product Azithromycin 200 mg/ 5 ml Powder for Oral Suspension 2. Qualitative and quantitative composition Each 5 ml prepared suspension contains 204.8 mg azithromycin monohydrate equivalent to 200 mg azithromycin. Each 1 ml prepared suspension contains 40.96 mg azithromycin monohydrate equivalent to 40 mg azithromycin. Excipients with known effect: • Sucrose 3.70 g/ 5 ml • Aspartame (E951) 0.030 g/ 5 ml For the full list of excipients, see section 6.1. 3. Pharmaceutical form Powder for oral suspension. White or off-white crystalline powder. 4. Clinical particulars 4.1 Therapeutic indications Azithromycin powder for oral suspension is indicated for the treatment of the following infections, when caused by microorganisms sensitive to azithromycin (see section 4.4 and 5.1): − acute bacterial sinusitis (adequately diagnosed) − acute bacterial otitis media (adequately diagnosed) − pharyngitis, tonsillitis − acute exacerbation of chronic bronchitis (adequately diagnosed) − mild to moderately severe community acquired pneumonia - skin and soft tissue infections - uncomplicated Chlamydia trachomatis urethritis and cervicitis Considerations should be given to official guidance on the appropriate use of antibacterial agents. 4.2 Posology and method of administration Adults In uncomplicated Chlamydia trachomatis urethritis and cervicitis, the dosage is 1,000 mg in one single oral dose. For all other indications the dosage is 1,500 mg, to be administered as 500 mg per day for three consecutive days. Alternatively the same total dosage (1,500 mg) can also be given over a period of 5 days with 500 mg on the first day and then 250 mg on days 2 to 5. To treat these patients other pharmaceutical forms are also available. Elderly The same dosage as in adult patients is used in the elderly. Since elderly patients can be patients with ongoing proarrhythmic conditions a particular caution is recommended due to the risk of developing cardiac arrhythmia and torsades de pointes (see section 4.4). Children and adolescents (< 18 years) The total dosage in children aged 1 year and older is 30 mg/kg administered as 10 mg/kg once daily for three days, or over a period of five days starting with a single dose of 10 mg/kg on the first day, followed by doses of 5 mg/kg per day for the following 4 days, according to the tables shown below. There are limited data on use in children younger than 1 year. The dosage for the treatment of pharyngitis caused by Streptococcus pyogenes is an exception: in the treatment of pharyngitis caused by Streptococcus pyogenes Azithromycin has proved to be effective when it is administered to children as a single dose of 10 mg/kg or 20 mg/kg for 3 days with a maximum daily dosage of 500 mg. At these two dosages a comparable clinical effect was observed, even if the eradication of the bacteria was more significant at a daily dosage of 20 mg/kg. Penicillin is however the drug of first choice in the treatment of pharyngitis caused by Streptococcus pyogenes and the prevention of subsequent rheumatic fever. Patients with renal impairment: No dose adjustment is necessary in patients with mild to moderate renal impairment (GFR 10-80 ml/min) (see section 4.4). Patients with hepatic impairment: A dose adjustment is not necessary for patients with mild to moderately impaired liver function (see section 4.4). Method of administration Before use the powder should be reconstituted with water into a white to off white, homogenous suspension, see section 6.6. After reconstitution the drug can be administered using a PE/PP syringe for oral use. After taking the suspension a bitter after-taste can be avoided by drinking fruit juice directly after swallowing. Azithromycin powder for oral suspension should be given in a single daily dosage. The suspension may be taken together with food. 4.3 Contraindications The use of this product is contraindicated in patients with hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide antibiotic, or to any of the excipients listed in section 6.1 (see also section 4.4). 4.4 Special warnings and precautions for use As with erythromycin and other macrolides, rare serious allergic reactions, including angioedema and anaphylaxis (rarely fatal), have been reported. Some of these reactions with azithromycin have resulted in recurrent symptoms and required a longer period of observation and treatment. Since liver is the principal route of elimination for azithromycin, the use of azithromycin should be undertaken with caution in patients with significant hepatic disease. Cases of fulminant hepatitis potentially leading to life-threatening liver failure have been reported with azithromycin (see section 4.8). Some patients may have had pre-existing hepatic disease or may have been taking other hepatotoxic medicinal products. In case of signs and symptoms of liver dysfunction, such as rapid developing asthenia associated with jaundice, dark urine, bleeding tendency or hepatic encephalopathy, liver function tests / investigations should be performed immediately. Azithromycin administration should be stopped if liver dysfunction has emerged. In patients receiving ergot derivatives, ergotism has been precipitated by co-administration of some macrolide antibiotics. There are no data concerning the possibility of an interaction between ergot and azithromycin. However, because of the theoretical possibility of ergotism, azithromycin and ergot derivatives should not be coadministered. As with any antibiotic preparation, observation for signs of superinfection with non- susceptible organisms, including fungi is recommended. Clostridium difficile associated diarrhoea (CDAD) has been reported with the use of nearly all antibacterial agents, including azithromycin, and may range in severity from mild diarrhoea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile. C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhoea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. In patients with severe renal impairment (GFR <10 ml/min) a 33% increase in systemic exposure to azithromycin was observed (see Section 5.2). Prolonged cardiac repolarisation and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been seen in treatment with macrolides including azithromycin (see section 4.8). Therefore as the following situations may lead to an increased risk for ventricular arrhythmias (including torsade de pointes) which can lead to cardiac arrest, azithromycin should be used with caution in patients with ongoing proarrhythmic conditions (especially women and elderly patients) such as patients: • With congenital or documented QT prolongation • Currently receiving treatment with other active substances known to prolong QT interval such as antiarrhythmics of class IA (quinidine and procainamide ) and class III (dofetilide, amiodarone and sotalol), cisapride and terfenadine; antipsychotic agents such as pimozide; antidepressants such as citalopram; and fluoroquinolones such as moxifloxacin and levofloxacin • With electrolyte disturbance, particularly in cases of hypokalaemia and hypomagnesemia • With clinically relevant bradycardia, cardiac arrhythmia or severe cardiac insufficiency Exacerbations of the symptoms of myasthenia gravis and new onset of myasthenia syndrome have been reported in patients receiving azithromycin therapy (see section 4.8). Safety and efficacy for the prevention or treatment of (Mycobacterium avium complex) in children have not been established. The following should be considered before prescribing azithromycin: Azithromycin powder for oral solution is not suitable for treatment of severe infections where a high concentration of the antibiotic in the blood is rapidly needed. Azithromycin is not the first choice for the empiric treatment of infections in areas where the prevalence of resistant isolates is 10% or more (see section 5.1). In areas with a high incidence of erythromycin A resistance, it is especially important to take into consideration the evolution of the pattern of susceptibility to azithromycin and other antibiotics. As for other macrolides, high resistance rates of Streptococcus pneumoniae (> 30 %) have been reported for azithromycin in some European countries (see section 5.1). This should be taken into account when treating infections caused by Streptococcus pneumoniae. Pharyngitis/ tonsilitis Azithromycin is not the substance of first choice for the treatment of pharyngitis and tonsillitis caused by Streptococcus pyogenes. For this and for the prophylaxis of acute rheumatic fever penicillin is the treatment of first choice. Sinusitis Often, azithromycin is not the substance of first choice for the treatment of sinusitis. Acute otitis media Often, azithromycin is not the substance of first choice for the treatment of acute otitis media. Skin and soft tissue infections The main causative agent of soft tissue infections, Staphylococcus aureus, is frequently resistant to azithromycin. Therefore, susceptibility testing is considered a precondition for treatment of soft tissue infections with azithromycin. Infected burn wounds Azithromycin is not indicated for the treatment of infected burn wounds. Sexually transmitted disease In case of sexually transmitted diseases a concomitant infection by T. palladium should be excluded. Neurological or psychiatric diseases Azithromycin should be used with caution in patients with neurological or psychiatric disorders. Caution in diabetic patients: 5 ml of reconstituted suspension contain 3.70 g of sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine since it contains sucrose. Azithromycin 200mg/5 ml contain aspartame which is a source of phenylalanine. It may be harmful for people with phenylketonuria. 4.5 Interaction with other medicinal products and other forms of interaction Antacids In a pharmacokinetic study investigating the effects of simultaneous administration of antacid with azithromycin, no effect on overall bioavailability was seen although peak serum concentrations were reduced by approximately 25%. In patients receiving both azithromycin and antacids, the drugs should not be taken simultaneously. Cetirizine In healthy volunteers, coadministration of a 5-day regimen of azithromycin with cetirizine 20 mg at steady-state resulted in no pharmacokinetic interaction and no significant changes in the QT interval. Didanosine (Dideoxyinosine) Coadministration of 1200 mg/day azithromycin with 400 mg/day didanosine in 6 HIV-positive subjects did not appear to affect the steady-state pharmacokinetics of didanosine as compared with placebo. Digoxin (P-gp substrates) Concomitant administration of macrolide antibiotics, including azithromycin, with P-glycoprotein substrates such as digoxin, has been reported to result in increased serum levels of the P-glycoprotein substrate. Therefore, if azithromycin and P-gp substrates such as digoxin are administered concomitantly, the possibility of elevated serum concentrations of the substrate should be considered. Zidovudine Single 1000 mg doses and multiple 1200 mg or 600 mg doses of azithromycin had little effect on the plasma pharmacokinetics or urinary excretion of zidovudine or its glucuronide metabolite. However, administration of azithromycin increased the concentrations of phosphorylated zidovudine, the clinically active metabolite, in peripheral blood mononuclear cells. The clinical significance of this finding is unclear, but it may be of benefit to patients. Azithromycin does not interact significantly with the hepatic cytochrome P450 system. It is not believed to undergo the pharmacokinetic drug interactions as seen with erythromycin and other macrolides. Hepatic cytochrome P450 induction or inactivation via cytochrome-metabolite complex does not occur with azithromycin. Ergot Due to the theoretical possibility of ergotism, the concurrent use of azithromycin with ergot derivatives is not recommended (see Section 4.4). Pharmacokinetic studies have been conducted between azithromycin and the following drugs known to undergo significant cytochrome P450 mediated metabolism. Ergotamine derivatives: Due to the theoretical possibility of ergotism, the concurrent use of azithromycin with ergot derivatives is not recommended (see section 4.4).Astemizole, alfentanil There are no known data on interactions with astemizole or alfentanil. Caution is advised in the co-administration of these medicines with Azithromycin because of the known enhancing effect of these medicines when used concurrently with the macrolid antibiotic erythromycin. Atorvastatin Coadministration of atorvastatin (10 mg daily) and azithromycin (500 mg daily) did not alter the plasma concentrations of atorvastatin (based on a HMG CoA-reductase inhibition assay). However, post-marketing cases of rhabdomyolysis in patients receiving azithromycin with statins have been reported. Carbamazepine In a pharmacokinetic interaction study in healthy volunteers, no significant effect was observed on the plasma levels of carbamazepine or its active metabolite in patients receiving concomitant azithromycin. Cisapride Cisapride is metabolized in the liver by the enzyme CYP 3A4. Because macrolides inhibit this enzyme, concomitant administration of cisapride may cause the increase of QT interval prolongation, ventricular arrhythmias and torsades de pointes. Cimetidine In a pharmacokinetic study investigating the effects of a single dose of cimetidine, given 2 hours before azithromycin, on the pharmacokinetics of azithromycin, no alteration of azithromycin pharmacokinetics was seen. Coumarin-Type Oral Anticoagulants In a pharmacokinetic interaction study, azithromycin did not alter the anticoagulant effect of a single 15 mg dose of warfarin administered to healthy volunteers. There have been reports received in the post-marketing period of potentiated anticoagulation subsequent to coadministration of azithromycin and coumarin-type oral anticoagulants. Although a causal relationship has not been established, consideration should be given to the frequency of monitoring prothrombin time when azithromycin is used in patients receiving coumarin-type oral anticoagulants. Cyclosporin In a pharmacokinetic study with healthy volunteers that were administered a 500 mg/day oral dose of azithromycin for 3 days and were then administered a single 10 mg/kg oral dose of cyclosporin, the resulting cyclosporin Cmax and AUC0-5 were found to be significantly elevated. Consequently, caution should be exercised before considering concurrent administration of these drugs. If coadministration of these drugs is necessary, cyclosporin levels should be monitored and the dose adjusted accordingly. Efavirenz Coadministration of a 600 mg single dose of azithromycin and 400 mg efavirenz daily for 7 days did not result in any clinically significant pharmacokinetic interactions. Fluconazole Coadministration of a single dose of 1200 mg azithromycin did not alter the pharmacokinetics of a single dose of 800 mg fluconazole. Total exposure and half-life of azithromycin were unchanged by the coadministration of fluconazole, however, a clinically insignificant decrease in Cmax (18%) of azithromycin was observed. Indinavir Coadministration of a single dose of 1200 mg azithromycin had no statistically significant effect on the pharmacokinetics of indinavir administered as 800 mg three times daily for 5 days. Methylprednisolone In a pharmacokinetic interaction study in healthy volunteers, azithromycin had no significant effect on the pharmacokinetics of methylprednisolone. Midazolam In healthy volunteers, coadministration of azithromycin 500 mg/day for 3 did not cause clinically significant changes in the pharmacokinetics and pharmacodynamics of a single 15 mg dose of midazolam. Nelfinavir Coadministration of azithromycin (1200 mg) and nelfinavir at steady state (750 mg three times daily) resulted in increased azithromycin concentrations. No clinically significant adverse effects were observed and no dose adjustment is required. Rifabutin Coadministration of azithromycin and rifabutin did not affect the serum concentrations of either drug. Neutropenia was observed in subjects receiving concomitant treatment of azithromycin and rifabutin. Although neutropenia has been associated with the use of rifabutin, a causal relationship to combination with azithromycin has not been established (see Section 4.8). Sildenafil In normal healthy male volunteers, there was no evidence of an effect of azithromycin (500 mg daily for 3 days) on the AUC and Cmax of sildenafil or its major circulating metabolite. Terfenadine Pharmacokinetic studies have reported no evidence of an interaction between azithromycin and terfenadine. There have been rare cases reported where the possibility of such an interaction could not be entirely excluded; however there was no specific evidence that such an interaction had occurred. Theophylline There is no evidence of a clinically significant pharmacokinetic interaction when azithromycin and theophylline are co-administered to healthy volunteers. Triazolam In 14 healthy volunteers, coadministration of azithromycin 500 mg on Day 1 and 250 mg on Day 2 with 0.125 mg triazolam on Day 2 had no significant effect on any of the pharmacokinetic variables for triazolam compared to triazolam and placebo. Trimethoprim/sulfamethoxazole Coadministration of trimethoprim/sulfamethoxazole (160 mg/800 mg) for 7 days with azithromycin 1200 mg on Day 7 had no significant effect on peak concentrations, total exposure or urinary excretion of either trimethoprim or sulfamethoxazole. Azithromycin serum concentrations were similar to those seen in other studies. Substances that prolong the QT interval Azithromycin should not be used concurrently with other active substances that prolong the QT interval (see section 4.4). 4.6 Fertility, pregnancy and lactation Pregnancy There are no adequate data from the use of Azithromycin in pregnant women. In reproduction toxicity studies in animals azithromycin was shown to pass the placenta, but no teratogenic effects were observed. The safety of azithromycin has not been confirmed with regard to the use of the active substance during pregnancy. Therefore Azithromycin should only be used during pregnancy if the benefit outweighs the risk. Lactation Azithromycin has been reported to be secreted into human breast milk, but there are no adequate and well-controlled clinical studies in nursing women that have characterized the pharmacokinetics of azithromycin excretion into human breast milk. Fertility In fertility studies conducted in rat, reduced pregnancy rates were noted following administration of azithromycin. The relevance of this finding to humans is unknown. 4.7 Effects on ability to drive and use machines There is no evidence to suggest that azithromycin may have an effect on a patient's ability to drive or operate machinery. 4.8 Undesirable effects The table below lists the adverse reactions identified through clinical trial experience and post-marketing surveillance by system organ class and frequency. The frequency grouping is defined using the following convention: Very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000); andnot known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. Adverse reactions possibly or probably related to azithromycin based on clinical trial experience and post-marketing surveillance: Adverse reactions possibly or probably related to Mycobacterium Avium Complex prophylaxis and treatment based on clinical trial experience and post-marketing surveillance. These adverse reactions differ from those reported with immediate release or the prolonged release formulations, either in kind or in frequency: Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme: www.mhra.gov.uk/yellowcard. 4.9 Overdose Adverse events experienced in higher than recommended doses were similar to those seen at normal doses. In the event of overdosage, general symptomatic and supportive measures are indicated as required 5. Pharmacological properties 5.1 Pharmacodynamic properties General properties Pharmacotherapeutic group: antibacterials for systemic use; macrolides; azithromycin, ATC code: J01FA10 Mode of action Azithromycin is an azalide, a sub-class of the macrolide antibiotics. By binding to the 50S-ribosomal sub-unit, azithromycin avoids the translocation of peptide chains from one side of the ribosome to the other. As a consequence of this, RNA-dependent protein synthesis in sensitive organisms is prevented. PK/PD relationship For azithromycin the AUC/MIC is the major PK/PD parameter correlating best with the efficacy of azithromycin. Mechanism of resistance Resistance to azithromycin may be inherent or acquired. There are three main mechanisms of resistance in bacteria: target site alteration, alteration in antibiotic transport and modification of the antibiotic. Complete cross resistance exists among Streptococcus pneumoniae, betahaemolytic streptococcus of group A, Enterococcus faecalis and Staphylococcus aureus, including methicillin resistant S. aureus (MRSA) to erythromycin, azithromycin, other macrolides and lincosamides. Breakpoints EUCAST (European Committee on Antimicrobial Susceptibility Testing) Susceptibility The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable. Pathogens for which resistance may be a problem: prevalence of resistance is equal to or greater than 10% in at least one country in the European Union. Table of susceptibility * Clinical effectiveness is demonstrated by sensitive isolated organisms for approved clinical indications. 5.2 Pharmacokinetic properties Absorption The biological availability of azithromycin after oral administration is approximately 37%. Peak plasma levels are achieved 2-3 hours after taking the medicinal product. Distribution After oral administration, azithromycin is distributed throughout the entire body. Pharmacokinetic studies have shown clearly higher azithromycin levels in the tissues than in the plasma (up to 50 times the maximum observed concentration in plasma). This indicates that the substance is bound in the tissues in considerable quantities. Concentrations in the infected tissues, such as lungs, tonsil and prostate are higher than the MRC90 of the most frequently occurring pathogens after a single dose of 500 mg. The protein binding of azithromycin in serum is variable and varies, depending on the serum concentration, from 52% at 0.05 mg/l to 12% at 0.5 mg/l. The steady state distribution volume is 31.1 l/kg. Elimination The terminal plasma-elimination half-life closely follows the tissue depletion half-life from 2 to 4 days. Approximately 12% of an intravenously administered dose of azithromycin is, over a period of 3 days, excreted unchanged in the urine. High concentrations of unchanged azithromycin were found in human bile. In this, ten metabolites were also detected (formed by N- and O- desmethylation, by hydroxylation of the desosamin and aglycon rings and by splitting the cladinose conjugate). A comparison of fluid chromatography and microbiological assessment methods shows that the metabolites are microbiologically inactive. In animal models high concentrations of azithromycin were found in phagocytes. Also it has been shown that during active phagocytosis higher concentrations of azithromycin are released than during inactive phagocytosis. In animal models this process was shown to contribute to the accumulation of azithromycin in infectious tissue. Pharmacokinetics in special populations Renal insufficiency Following a single oral dose of azithromycin 1 g, mean Cmax and AUC0-120 increased by 5.1% and 4.2% respectively, in subjects with mild to moderate renal impairment (glomerular filtration rate of 10-80 ml/min) compared with normal renal function (GFR > 80 ml/min). In subjects with severe renal impairment, the mean Cmax and AUC0-120 increased 61% and 33% respectively compared to normal. Hepatic insufficiency In patients with mild to moderate hepatic impairment, there is no evidence of a marked change in serum pharmacokinetics of azithromycin compared to normal hepatic function. In these patients, urinary recovery of azithromycin appears to increase perhaps to compensate for reduced hepatic clearance. Elderly The pharmacokinetics of azithromycin in elderly men was similar to that of young adults; however, in elderly women, although higher peak concentrations (increased by 30-50%) were observed, no significant accumulation occurred. Infants, toddlers, children and adolescents Pharmacokinetics have been studied in children aged 4 months – 15 years taking capsules, granules or suspension.. At 10 mg/kg on day 1 followed by 5 mg/kg on days 2-5, the Cmax achieved is slightly lower than adults with 224 ug/l in children aged 0.6-5 years and after 3 days dosing and 383 ug/l in those aged 6-15 years. The t1/2 of 36 h in the older children was within the expected range for adults. 5.3 Preclinical safety data In animal tests in which the dosages used amounted to 40 times the clinical therapeutic dosages, azithromycin was found to have caused reversible phospholipidosis, but as a rule no true toxicological consequences were observed which were associated with this. The relevance of this finding to humans receiving azithromycin in accordance with the recommendations is unknown. Electrophysiological investigations have shown that azithromycin prolongs the QT interval. Mutagenic potential: There was no evidence of a potential for genetic and chromosome mutations in in-vivo and in-vitro test models. Reproductive toxicity: In embryotoxicity studies in mice and rats no teratogenic effects were observed. In rats, azithromycin dosages of 100 and 200 mg/kg bodyweight/day led to slight retardations in fetal ossification and in maternal weight gain. In peri-/postnatal studies in rats, slight retardations in physical development and delay in reflex development were observed following treatment with 50 mg/kg/day azithromycin and above. 6. Pharmaceutical particulars 6.1 List of excipients Sucrose Xanthan gum Hydroxypropylcellulose Trisodium phosphate anhydrous Silica, colloidal anhydrous (E551) Aspartame (E951) Cream caramel flavour Titanium dioxide (E171) 6.2 Incompatibilities Not applicable. 6.3 Shelf life Unopened bottle with dry powder: 36 months. Reconstituted suspension: 10 days. 6.4 Special precautions for storage Unopened bottle: Do not store above 30°C. Reconstituted suspension: Do not store above 25°C. 6.5 Nature and contents of container HDPE bottles with a PP/ PE- closure with retaining ring. PE/PP-dosage syringe (10 ml), graduated in 0.25 ml divisions. Content of the bottle after reconstitution: 15 ml (600 mg), 20 ml (800 mg), 22.5 ml (900 mg), 30 ml (1,200 mg) or 37.5 ml (1,500 mg). A plastic dosage syringe (10 ml), graduated in 0.25 ml divisions is also included. Not all pack sizes may be marketed. 6.6 Special precautions for disposal and other handling Preparation of the suspension: Shake the dry powder loose. Add the amount of water described below to the powder. For 15 ml (600 mg) reconstituted suspension: add 7.5 ml water. For 20 ml (800 mg) reconstituted suspension: add 10.0 ml water. For 22.5 ml (900 mg) reconstituted suspension: add 11.0 ml water. For 30 ml (1,200 mg) reconstituted suspension: add 15.0 ml water. For 37.5 ml (1,500 mg) reconstituted suspension: add 18.5 ml water. Shake well until a white to off white coloured, homogenous suspension is achieved. For administration the syringe adapter should be placed in the neck of the bottle and the stopper should be opened. 7. Marketing authorisation holder Sandoz Ltd Frimley Business Park Frimley Camberley Surrey GU16 7SR United Kingdom 8. Marketing authorisation number(s) PL 04416/0782 9. Date of first authorisation/renewal of the authorisation 06/08/2007 10. Date of revision of the text 06/03/2014 http://www.medicines.org.uk/emc/medicine/22608